Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
KOOL's Cash to Debt is ranked higher than
97% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. KOOL: No Debt )
KOOL' s 10-Year Cash to Debt Range
Min: 0.87   Max: No Debt
Current: No Debt

Equity to Asset 0.87
KOOL's Equity to Asset is ranked higher than
93% of the 367 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. KOOL: 0.87 )
KOOL' s 10-Year Equity to Asset Range
Min: 0.45   Max: 0.91
Current: 0.87

0.45
0.91
Interest Coverage No Debt
KOOL's Interest Coverage is ranked higher than
77% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 117.58 vs. KOOL: No Debt )
KOOL' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 1.34
M-Score: 15.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -17.06
KOOL's Operating margin (%) is ranked higher than
55% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. KOOL: -17.06 )
KOOL' s 10-Year Operating margin (%) Range
Min: -211.11   Max: -9.09
Current: -17.06

-211.11
-9.09
Net-margin (%) -17.18
KOOL's Net-margin (%) is ranked higher than
55% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. KOOL: -17.18 )
KOOL' s 10-Year Net-margin (%) Range
Min: -213.33   Max: -3.03
Current: -17.18

-213.33
-3.03
ROE (%) -23.17
KOOL's ROE (%) is ranked higher than
55% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. KOOL: -23.17 )
KOOL' s 10-Year ROE (%) Range
Min: -171.43   Max: -5
Current: -23.17

-171.43
-5
ROA (%) -16.65
KOOL's ROA (%) is ranked higher than
55% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. KOOL: -16.65 )
KOOL' s 10-Year ROA (%) Range
Min: -123.08   Max: -3.7
Current: -16.65

-123.08
-3.7
ROC (Joel Greenblatt) (%) -47.53
KOOL's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 13.35 vs. KOOL: -47.53 )
KOOL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -256.76   Max: -18.75
Current: -47.53

-256.76
-18.75
Revenue Growth (%) -12.90
KOOL's Revenue Growth (%) is ranked higher than
51% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. KOOL: -12.90 )
KOOL' s 10-Year Revenue Growth (%) Range
Min: -24.7   Max: 20.4
Current: -12.9

-24.7
20.4
EBITDA Growth (%) -23.90
KOOL's EBITDA Growth (%) is ranked higher than
57% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. KOOL: -23.90 )
KOOL' s 10-Year EBITDA Growth (%) Range
Min: -38.9   Max: 270.2
Current: -23.9

-38.9
270.2
EPS Growth (%) -19.90
KOOL's EPS Growth (%) is ranked higher than
62% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. KOOL: -19.90 )
KOOL' s 10-Year EPS Growth (%) Range
Min: -36.4   Max: 278
Current: -19.9

-36.4
278
» KOOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

KOOL Guru Trades in Q2 2013

Jim Simons 191,000 sh (+2.85%)
» More
Q3 2013

KOOL Guru Trades in Q3 2013

Jim Simons 222,000 sh (+16.23%)
» More
Q4 2013

KOOL Guru Trades in Q4 2013

Jim Simons 187,700 sh (-15.45%)
» More
Q1 2014

KOOL Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KOOL



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.12
KOOL's P/B is ranked higher than
92% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. KOOL: 1.12 )
KOOL' s 10-Year P/B Range
Min: 0.16   Max: 5.18
Current: 1.12

0.16
5.18
P/S 1.60
KOOL's P/S is ranked higher than
80% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. KOOL: 1.60 )
KOOL' s 10-Year P/S Range
Min: 0.18   Max: 6.52
Current: 1.6

0.18
6.52
EV-to-EBIT -4.85
KOOL's EV-to-EBIT is ranked higher than
57% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 44.56 vs. KOOL: -4.85 )
KOOL' s 10-Year EV-to-EBIT Range
Min: 2.3   Max: 10.3
Current: -4.85

2.3
10.3
Current Ratio 3.12
KOOL's Current Ratio is ranked higher than
72% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. KOOL: 3.12 )
KOOL' s 10-Year Current Ratio Range
Min: 1.52   Max: 16.85
Current: 3.12

1.52
16.85
Quick Ratio 2.25
KOOL's Quick Ratio is ranked higher than
71% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. KOOL: 2.25 )
KOOL' s 10-Year Quick Ratio Range
Min: 0.86   Max: 15.88
Current: 2.25

0.86
15.88

Valuation & Return

vs
industry
vs
history
Price/Net Cash 70.50
KOOL's Price/Net Cash is ranked higher than
81% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. KOOL: 70.50 )
KOOL' s 10-Year Price/Net Cash Range
Min: 0.46   Max: 241
Current: 70.5

0.46
241
Price/Net Current Asset Value 6.41
KOOL's Price/Net Current Asset Value is ranked higher than
91% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. KOOL: 6.41 )
KOOL' s 10-Year Price/Net Current Asset Value Range
Min: 0.3   Max: 71.88
Current: 6.41

0.3
71.88
Price/Tangible Book 3.36
KOOL's Price/Tangible Book is ranked higher than
78% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. KOOL: 3.36 )
KOOL' s 10-Year Price/Tangible Book Range
Min: 0.23   Max: 36.11
Current: 3.36

0.23
36.11
Price/Median PS Value 1.20
KOOL's Price/Median PS Value is ranked higher than
69% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. KOOL: 1.20 )
KOOL' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 11.47
Current: 1.2

0.19
11.47
Earnings Yield (Greenblatt) 88.40
KOOL's Earnings Yield (Greenblatt) is ranked higher than
99% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. KOOL: 88.40 )
KOOL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 9.7   Max: 174.6
Current: 88.4

9.7
174.6
Forward Rate of Return (Yacktman) -41.66
KOOL's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.97 vs. KOOL: -41.66 )
KOOL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -101.5   Max: -71.3
Current: -41.66

-101.5
-71.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:THRA.Germany
Thermogenesis Corporation was incorporated in Delaware in July 1986. The Company designs, manufactures and markets automated and semi-automated devices and single-use processing disposables that enable hospitals and blood banks to manufacture a therapeutic dose of stem cells. Initially, the Company developed medical devices for ultra rapid freezing and thawing of blood components, which the Company manufactures and distributes to blood banks and hospitals. The Company's products automate the volume reduction and cryopreservation process of adult stem cell concentrates from cord blood and bone marrow for use in laboratory and point of care settings. It currently sells its products in approximately 37 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. It provides the tools necessary for the collection, separation, storage and delivery of stem cells from adult tissue sources including cord blood and bone marrow, and potentially in the future, adipose and placenta. These tools are being used by healthcare providers in both the laboratory and point of care settings. The Company's competitive advantage is achieved through applying its advanced research and engineering capabilities to develop a complete 'tool box' for healthcare providers advancing regenerative medicine. The Company's solutions enable its customers to automate their processes, comply with quality regulations and achieve high stem cell yields. The Company's medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies.
» More Articles for KOOL

Headlines

Articles On GuruFocus.com
comment on KOOL Dec 01 2011 
comment on KOOL Aug 26 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
CESCA Management Provides Regulatory Update on Its Proposed U.S. Pivotal Critical Limb Ischemia... Jul 08 2014
Coverage initiated on Cesca Therapeutics by H.C. Wainwright Jun 26 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 16 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 13 2014
Cesca Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants Jun 13 2014
Cesca Therapeutics Announces Proposed Public Offering Jun 12 2014
Cesca Therapeutics Announces Promising Longer-Term Safety and Efficacy Data on SurgWerks(R)-CLI From... Jun 10 2014
Cesca Therapeutics to Present at LD Microcap Conference Jun 03 2014
CESCA THERAPEUTICS INC. Financials May 23 2014
Cesca Therapeutics to Present at the Third Annual Marcum Microcap Conference May 23 2014
Cesca Therapeutics files $50M mixed securities shelf May 21 2014
Cesca Therapeutics' (KOOL) CEO Matthew Plavan on Q3 2014 Results - Earnings Call Transcript May 15 2014
Cesca Therapeutics reports Q3 EPS (7c) vs. (7c) in Q313 May 15 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 15 2014
CESCA THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report May 15 2014
Cesca Therapeutics Reports Third Quarter Fiscal 2014 Results May 15 2014
Cesca Therapeutics to Announce Third Quarter Fiscal 2014 Results on May 15, 2014 May 13 2014
Cesca Therapeutics Announces the Appointment of Dr. Solomon Hamburg to Newly Formed Clinical and... May 12 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments... May 01 2014
Cesca Executive Management Meets With Key Congressional Leaders on the Regenerative Medicine... Apr 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide